Photo from wikipedia
Nivolumab is a programmed death-1 (PD1) immune checkpoint inhibitor that treats various types of cancers including non-small cell lung carcinoma and melanoma, among others. Although it serves as an effective… Click to show full abstract
Nivolumab is a programmed death-1 (PD1) immune checkpoint inhibitor that treats various types of cancers including non-small cell lung carcinoma and melanoma, among others. Although it serves as an effective immunotherapy, there are many associated immune-related adverse events. Even years after the introduction of nivolumab, the breadth of its side effect profile continues to expand. We present a case of squamous cell carcinoma associated with nivolumab treatment for metastatic melanoma.
Keywords:
cell carcinoma;
cell;
associated nivolumab;
melanoma;
squamous cell;
nivolumab treatment
Journal Title: Dermatology online journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Dermatology online journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!